Key facts
- This page summarizes Robert J. More's Form 4 filing for Vir Biotechnology, Inc. (VIR).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2026, 14:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Other
Other
Additional SEC filing notes
Footnote F1
Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards.
Footnote F2
The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.